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Deficiency in complement component C1q is associated with an inability to clear apop-
totic cells (efferocytosis) and aberrant inflammation in lupus, and identification of the 
pathways involved in these processes should reveal important regulatory mechanisms in 
lupus and other autoimmune or inflammatory diseases. In this study, C1q-dependent reg-
ulation of TNFα/IL-6 expression and efferocytosis was investigated using primary mouse 
bone marrow-derived macrophages and human monocyte-derived macrophages. C1q 
downregulated LPS-dependent TNFα production in mouse and human macrophages. 
While prolonged stimulation with C1q (18 h) was required to elicit a dampening of TNFα 
production from mouse macrophages, the human macrophages responded to C1q with 
immediate downregulation of TNFα. IL-6 production was unchanged in mouse and upreg-
ulated by human macrophages following prolonged stimulation with C1q. Our previous 
studies indicated that C1q programmed enhanced efferocytosis in mouse macrophages 
by enhancing expression of Mer tyrosine kinase and its ligand Gas6, a receptor–ligand pair 
that also inhibits proinflammatory signaling. Here, we demonstrated that C1q-dependent 
programming of human macrophage efferocytosis required protein synthesis; however, 
neither Mer nor the related receptor Axl was upregulated in human cells. In addition, 
while the C1q-collagen-like tails are sufficient for promoting C1q-dependent phagocytosis 
of antibody-coated targets, the C1q-tails failed to program enhanced efferocytosis or 
dampen TNFα production. These data further elucidate the mechanisms by which C1q 
regulates proinflammatory signaling and efferocytosis in macrophages, functions that are 
likely to influence the progression of autoimmunity and chronic inflammation.
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inTrODUcTiOn
C1q, well known for its function as the recognition component of the classical complement pathway, 
also functions independently of the complement system to facilitate phagocytosis and regulate pro-
inflammatory signaling in myeloid cells [reviewed in Bohlson et al. (1)]. To this end, in vitro studies 
demonstrate that C1q and other members of the defense collagen family, such as mannose-binding 
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lectin (MBL) and surfactant protein-A (SP-A), are bridging mol-
ecules that bind to target particles, such as pathogens or apoptotic 
cells, and facilitate their rapid clearance [reviewed in Galvan et al. 
(2)]. C1q deficiency is associated with the development of auto-
immunity, which is thought to result from an inefficient clearance 
of apoptotic cells or “efferocytosis,” and apoptotic/dying cells are 
considered to be a source of lupus autoantigens (3). While the 
function of C1q as a bridging molecule that physically links the 
apoptotic cell to the phagocyte has been appreciated for years, 
more recent studies indicate an additional function for C1q in 
macrophage polarization. C1q programs macrophages to an anti-
inflammatory and pro-efferocytic phenotype, consistent with an 
M2-like phenotype (4–6). Physical bridging and programming 
may occur concomitantly; however, little is known about the 
molecular mechanisms leading to C1q-dependent regulation of 
the macrophage phenotype.
Korb and Ahearn (7) were the first to demonstrate that C1q 
binds directly and specifically to apoptotic cells using human 
apoptotic keratinocytes. This work led to a series of support-
ing studies that demonstrated that C1q bridges apoptotic cells 
to phagocytes to facilitate the rapid removal of cellular debris 
in both mouse and human phagocytes [reviewed in Galvan 
et al. (2)]. Using primary human monocytes, macrophages and 
dendritic cells, Fraser and colleagues demonstrated that immo-
bilized C1q bound to apoptotic cells inhibited LPS-dependent 
TNFα production in human macrophages but did not stimulate 
efferocytosis unless serum was present, resulting in activation 
of the classical complement pathway and deposition of C3b 
(8). In addition, C1q-opsonized autologous human apoptotic 
lymphocytes inhibited activation of the NLRP3 inflammasome 
and skewed human macrophages toward an anti-inflammatory 
phenotype (4). Furthermore, Clarke et al. (9) demonstrated that 
C1q-bound apoptotic cells suppressed human macrophage and 
dendritic cell-mediated TH17 and TH1 T cell subset proliferation 
suggesting that T-cell-mediated immune responses are altered 
when C1q serves as an opsonin for a target particle. Apoptotic 
cells alone are anti-inflammatory, and these studies suggest 
that C1q-opsonization further enhances the anti-inflammatory 
properties of apoptotic cells.
In our previous studies, to determine if C1q could program 
macrophages toward an anti-inflammatory and pro-efferocytic 
phenotype in the absence of apoptotic cells, we stimulated 
mouse macrophages with C1q and investigated changes in gene 
expression by microarray. We demonstrated that C1q stimulation 
resulted in expression of pro-efferocytic molecules, including 
Mer tyrosine kinase (Mer) and its ligand Gas6 (5). This finding is 
consistent with the report that expression of pro-efferocytic mol-
ecules is decreased in macrophages from human lupus patients 
(10). Mer is a member of the Tyro, Axl, and Mer (TAM) family 
of receptor tyrosine kinases that regulate efferocytosis and down-
regulate proinflammatory signaling in myeloid cells [reviewed 
in Lemke and Rothlin (11)]. C1q-dependent efferocytosis was 
dependent on Mer/Gas6 in mouse macrophages, and this was 
the first demonstration that C1q could program efferocytosis 
independent of its role as an opsonin (2). In the current study, we 
sought to further define the role of C1q in programming the mac-
rophage phenotype. To do this, we incubated human and mouse 
primary macrophages on immobilized C1q prior to the addition 
of apoptotic cells to differentiate the role of C1q in macrophage 
programming from the opsonic activity of C1q and compare 
responses in primary mouse and human cells. The data suggest 
that C1q programs human and mouse macrophages toward a 
pro-efferocytic phenotype and also programs altered cytokine 
signaling. This programming may be important in autoimmune 
diseases, such as lupus, where dysregulated macrophage activa-
tion may contribute to chronic inflammation.
MaTerials anD MeThODs
Dulbecco’s Modified Eagle’s Medium (DMEM) and RPMI 1640 
were purchased from Gibco/Life Technologies (Grand Island, 
NY, USA). Chemically defined, serum-free medium (HL1) was 
obtained from Lonza (Walkersville, MD, USA) and supplemented 
with 1% l-alanyl-l-glutamine (Corning, Inc., Corning, NY, USA), 
10-mM HEPES and 5-mM MgCl2. Penicillin/streptomycin solu-
tion was purchased from Gibco/Life Technologies. Fetal bovine 
serum (FBS) was purchased from HyClone Laboratories/GE 
Healthcare Life Sciences (Logan, UT, USA) and heat inactivated 
at 56°C for 30 min. Bovine serum albumin (BSA) was purchased 
from Sigma-Aldrich (St. Louis, MO, USA). C1q was purified 
from normal human plasma as previously described in detail 
(12, 13). Briefly, pooled normal human serum was separated by 
ion-exchange chromatography (BioRex 70). After extensive wash-
ing, the bound C1q was eluted with a salt gradient of 0.082–0.3M 
NaCl containing 0.05M phosphate and 2-mM EDTA. Fractions 
containing C1q as determined by hemolytic assay were pooled 
and precipitated with 33% ammonium sulfate. The purified C1q 
was redissolved and separated by size-exclusion chromatography 
(Biogel A5m). The C1q-containing fractions were again concen-
trated with ammonium sulfate, dialyzed, and stored at −80°C. The 
purified C1q is hemolytically active, and homogeneous as assessed 
by SDS-PAGE. Evidence for the immunochemical purity of the 
C1q has been extensively described (12). The C1q preparation 
was free of endotoxin as determined by the LAL Chromogenic 
Endotoxin Quantitation Kit (Fisher Scientific, Rockford, IL, 
USA). Dr. Andrea Tenner (University of California, Irvine, Irvine, 
CA, USA) kindly provided the C1q collagen-like tails used in our 
studies. Human serum albumin (HSA) was purchased from Baxter 
(Deerfield, IL, USA). Cycloheximide was purchased from Chem 
Service (West Chester, PA, USA) and dissolved in endotoxin-free 
water at a concentration of 25  mM. CFSE was purchased from 
Invitrogen/Life Technologies (Grand Island, NY, USA) and recon-
stituted to 5 mM in DMSO. Etoposide (Sigma) was reconstituted 
to 10 mM in DMSO. Ultra-pure LPS from Escherichia coli 055.B5 
was from List Biological Laboratories (Campbell, CA, USA).
antibodies
Rabbit anti-mouse Mer primary antibody and goat anti-mouse 
Axl were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Rabbit anti-human Mer primary antibody was 
purchased from Abcam (Cambridge, MA, USA) and goat anti-
human Axl was purchased from R&D Systems (Minneapolis, 
MN, USA). Mouse anti-actin primary antibody was purchased 
from Sigma-Aldrich. HRP-conjugated secondary antibodies 
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were purchased from Jackson ImmunoResearch (West Grove, 
PA, USA). Isotype control and phycoerythrin-tagged CD11b 
antibodies were purchased from eBioscience.
Mice
All mice were of a C57Bl/6 background. Mice were housed in a 
pathogen-free facility in the Des Moines University animal care 
facility. All methods were performed in accordance with proto-
cols approved by the Des Moines University Institutional Animal 
Care and Use Committee.
Mouse cell culture
Bone marrow-derived macrophages (BMDM) were generated 
as previously described (14). Femurs and tibias were removed 
from 6- to 12-week-old C57Bl/6, and bone marrow was flushed 
from the bones with DMEM containing 5% heat-inactivated FBS, 
10-mM HEPES, and 100 units/ml penicillin G sodium/100 μg/
ml streptomycin sulfate (Pen/Strep). Cells were cultured in 
DMEM containing 5% heat-inactivated FBS, 10-mM HEPES, 
and Pen/Strep at 37°C and 5% CO2 for 2 h to remove any resident 
fibroblasts or macrophages. Non-adherent cells were cultured in 
BMDM medium (DMEM, 15% L929 conditioned medium, 10% 
heat-inactivated FBS, Pen/Strep, and 10-mM HEPES) at 37°C 
and 5% CO2 for 4 days, and media was replaced. Cells were fully 
mature by day 7. Media was replaced every 2–3 days and cells 
were passed every 7 days to maintain viability (15).
human cell culture
Heparinized whole blood (100 ml) was obtained by venipuncture 
from healthy human donors, diluted 1:1 in endotoxin-free sterile 
saline, and separated into components by gradient centrifuga-
tion using lymphocyte separation medium (MP Biomedicals, 
Solon, OH, USA). Mononuclear cells were collected, washed 
three times with RPMI 1640, and the monocytes were isolated 
through negative selection using magnetic Dynabeads according 
to the manufacturer’s protocol (Invitrogen/Life Technologies). 
Monocytes were cultured in RPMI supplemented with 20% 
human AB+ serum (Fisher Scientific) and Pen/Strep at 37°C and 
5% CO2. After a 4-day maturation period, media was replaced 
and human monocyte-derived macrophages (HMDM) were 
harvested for assays on day 7. The human Jurkat T cell line was 
purchased from ATCC (Manassas, VA, USA) and cultured in 
RPMI supplemented with 10% heat-inactivated FBS and Pen/
Strep. All procedures were approved by the Des Moines University 
Institutional Review Board before initiation, and all procedures 
performed were in accordance with the approved protocol.
Phagocytosis assays
Sheep erythrocytes were suboptimally opsonized with rabbit anti-
sheep IgG (EAIgG) as previously described (16). Briefly, anti-sheep 
IgG was isolated from anti-sheep hemolysin (Colorado Serum 
Company, Denver, CO, USA) using GammaBind G Sepharose 
(GE Healthcare, Pittsburgh, PA, USA). EAIgG phagocytosis 
assays were performed as described (17). Percent phagocytosis 
was calculated as the number of macrophages that ingested at least 
one EAIgG divided by the total number of macrophages counted, 
multiplied by 100. At least 200 macrophages per well were scored 
by microscopy under oil immersion and by individuals blinded 
to the experimental conditions; all experimental conditions were 
performed in duplicate.
For clarity throughout the manuscript, assays that measured 
engulfment of EAIgG are referred to as “phagocytosis,” whereas 
assays that measured the engulfment of apoptotic cells are 
referred to as “efferocytosis.” Efferocytosis assays were performed 
as follows: four-well Lab-Tek Chamber Slides (Nunc/Thermo 
Fisher Scientific, Rochester, NY, USA) were coated with 400 μl of 
full-length C1q, C1q collagen-like tails, or human serum albumin 
(HSA) at 4–8 μg/ml for 2 h at room temperature. Concentrations 
of 4 and 8  μg/ml stimulate C1q-dependent functions without 
significant changes in background (HSA) activity. The wells 
were gently washed twice with PBS before adding 500  μl of 
macrophages at a concentration of 5 × 105/ml in supplemented 
HL1. Cells were allowed to adhere for the times indicated in 
figure legends. Jurkat cells were labeled with 5  μM CFSE for 
30 min at 37°C and washed with complete media twice before 
the addition of 40 μM etoposide for 15  h to induce apoptosis. 
Apoptotic Jurkats were washed twice with phagocytosis buffer 
(RPMI supplemented with 5-mM MgCl2 and Pen/Strep) before 
being added at a 3:1 ratio of targets to macrophages. Slides were 
centrifuged at 700 rpm for 3 min and incubated at 37°C and 5% 
CO2 for 1 h. After incubation, slides were gently washed with PBS 
twice to remove non-ingested targets, and cells were trypsinized, 
collected into FACS buffer (Hank’s Balanced Salt Solution sup-
plemented with 0.2% BSA), washed, and stained with CD11b-PE 
antibody. Efferocytosis assays were analyzed by flow cytometry 
as described (17), and percent efferocytosis was calculated as the 
number of cells positive for both CD11b-PE and CFSE, divided 
by the total number of CD11b-PE-positive cells, multiplied by 
100. Percentage of apoptotic cells was measured for each assay 
using Annexin V and propidium iodide staining (Table S1 in 
Supplementary Material).
Western Blotting
Lab-Tek chamber slides were coated with 2 ml of 4–8 μg/ml HSA 
or C1q for 2 h before the addition of 106 BMDM or 5 × 105 HMDM 
in supplemented HL1. At the indicated time points, whole-cell 
lysates were collected with RIPA buffer (50  mM Tris–HCl pH 
7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, and 
1% Triton-X) supplemented with 10 mM sodium fluoride, 2 mM 
EDTA, 1  mM PMSF, and protease and phosphatase inhibitor 
tablets (Roche, Indianapolis, IN, USA). Total protein concentra-
tion was calculated by BCA assay according to the manufacturer’s 
protocol (Thermo Scientific, Rockford, IL, USA), and 14–20 μg 
protein was resolved using 10% SDS-PAGE under reducing con-
ditions. Protein samples were transferred to a PVDF membrane 
and blocked for at least 1 h. Membranes were then probed with 
antibodies as described in the figure legends and developed using 
enhanced chemiluminescent reagents (GE Healthcare).
cytokine assays
Lab-Tek chamber slides were coated with HSA, C1q, or C1q 
collagen-like tails at 4–8 μg/ml for 2 h. BMDM or HMDM were 
harvested using PBS containing 10  mM EDTA, washed, and 
resuspended in supplemented HL1. The 5 × 105 HMDM or 106 
FigUre 1 | c1q programs an alteration in cytokine signaling in mouse 
bone marrow-derived macrophages and human monocyte-derived 
macrophages. BMDM or HMDM were adhered to C1q- or HSA (control)-
coated Lab-Tek Chamber (LTC) slides for 30 min or 18 h, as indicated in 
individual graph titles. Cells were then stimulated with 300 ng/ml LPS for 4 h 
and TNF-α or IL-6 was quantified by ELISA from supernatants according to 
manufacturer’s protocol. Bars represent the average cytokine production of 
C1q relative to HSA from three (e,g,h), four (c), five (D), six (a), seven (F), 
or eight (B) individual experiments ± SEM. *p < 0.05; **p < 0.01; 
***p = 0.001; n.s. = not significant.
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BMDM were added to the wells and allowed to adhere for 30 min 
or 18 h. Cells were then activated with LPS (300 ng/ml) for 4 h. 
Supernatants were collected, and TNFα and/or IL-6 were quanti-
fied by Ready-Set-Go ELISA kits, according to the manufacturer’s 
protocol (eBioscience).
statistical analysis
Due to variability in total cytokine levels between human donors 
and mice, descriptive statistics in Figures 1, 2, 4 and 5 were pre-
sented as relative means from combined experiments with SEs. 
For phagocytosis and efferocytosis experiments that were col-
lected as counts/percentage data, an arcsine square root transfor-
mation was first performed. For better approximation to normal 
distribution, the Western blot data in Figure 4B were normalized 
to the internal controls as ratios and further log transformed on 
the base 2 log scale before the linear model analysis below. The 
cytokine (ELISA) data in Figures 1 and 5 were log transformed 
on the base 2 log scale. Analysis of variance (ANOVA) was then 
performed on the properly transformed data sets using a linear 
model that accounts for the different sources of variation, treat-
ment, and experiment. The comparisons of interest were made 
using statistical contrasts of the treatment factor in the ANOVA. 
Multiple comparison adjustment was made with Bonferroni or 
Tukey procedure where appropriate. The p-value < 0.05 is con-
sidered to be significant.
resUlTs
c1q Programs an alteration in cytokine 
signaling in Mouse Bone Marrow-Derived 
Macrophages and human Monocyte-
Derived Macrophages
Previous studies have shown that C1q provides a direct inhibition 
of proinflammatory signaling in a variety of myeloid cells (4, 6, 
8, 18–21). However, when mouse BMDM were stimulated with 
C1q for 30 min and then activated with lipopolysaccharide (LPS), 
control, and C1q-stimulated BMDM secreted equivalent levels 
of TNFα (Figure 1A). In contrast, BMDM that were stimulated 
with C1q for 18 h secreted significantly less TNFα compared to 
control cells (Figure 1B, range of inhibition 12.4–55.9%, n = 8). 
This suggests that BMDM require a C1q-dependent program-
ming event in order to respond to C1q with this diminished 
proinflammatory response. Similar experiments were performed 
with HMDM, and unlike BMDM, there was a direct inhibition of 
proinflammatory signaling in the HMDM; HMDM stimulated 
with C1q for 30  min and then activated with LPS produced 
significantly less TNFα compared to control cells (Figure  1C, 
range of inhibition 60.2–87.6%, n =  4). In addition, HMDM 
that were stimulated with C1q for 18 h prior to treatment with 
LPS produced significantly less TNFα compared to control cells 
(Figure 1D, range of inhibition 30.9–40.4%, n = 5). Importantly, 
both BMDM and HMDM that were not stimulated with LPS 
produced little or no proinflammatory cytokines (Figure S1 in 
Supplementary Material). While IL-6 production was not sig-
nificantly altered in BMDM after 30 min or 18 h stimulation with 
C1q (Figures 1E,F), IL-6 production was enhanced in HMDM. 
C1q-stimulated HMDM produced equivalent amounts of IL-6 
compared to control after 30 min stimulation (Figure 1G), but 
produced a significantly higher amount of IL-6 following 18 h 
programming with C1q. There was a 2.2- to 3.9-fold increase 
in IL-6 production in HMDM pre-stimulated with C1q for 18 h 
(Figure 1H, n = 3). These data demonstrate that C1q regulates 
IL-6 and TNFα production in macrophages, and some activities 
require prolonged programming with C1q.
c1q stimulates Programmed efferocytosis 
in Mouse and human Macrophages and is 
Dependent on Protein synthesis
Our previous studies demonstrated that C1q-programmed mouse 
BMDM to express pro-efferocytic molecules, and as a result there 
FigUre 2 | c1q stimulates programmed efferocytosis in human monocyte-derived macrophages, but not primary human monocytes. (a) Primary 
human monocytes were cultured in LTC slides coated with 8 μg/ml HSA (control) or C1q for 18 h and fed CFSE-labeled apoptotic Jurkats at a 3:1 ratio of targets to 
macrophages for 1 h. Efferocytosis was quantified by flow cytometry. Bars represent average efferocytosis of C1q relative to HSA from three experiments ± SEM. 
n.s. = not significant. (B) Human monocyte-derived macrophages (MDM) were cultured as in (a) for 30 min or 18 h and fed CFSE-labeled apoptotic Jurkats at a 3:1 
ratio of targets to macrophages for 1 h. Efferocytosis was quantified by flow cytometry. Bars represent average efferocytosis of C1q relative to HSA from three 
experiments (30 min) or four experiments (18 h) ± SEM. n.s. = not significant (p = 0.052); ***p < 0.001. (c) Representative flow cytometry scatter plots from one 
experiment as described in (B).
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was enhanced efferocytic activity in C1q-programmed BMDM. 
The enhanced efferocytic activity required C1q-dependent expres-
sion of Mer tyrosine kinase (Mer) and its ligand Gas6 (2). To deter-
mine if C1q-dependent programmed efferocytosis occurred in 
human cells, human monocytes and HMDM were stimulated with 
C1q for 18 h, and efferocytosis was measured. C1q-programmed 
monocytes engulfed the same number of apoptotic cells as the 
control monocytes (Figure  2A, n  =  3). In contrast, HMDM 
engulfed twofold more apoptotic cells compared to control cells 
after a 30-min stimulation with C1q and greater than fivefold after 
18 h of C1q stimulation (Figure 2B, n = 3 and Figure 2C, n = 4). 
These data suggested that the maturation state and culture condi-
tions of the macrophage dictated its ability to respond to C1q with 
programmed efferocytosis. Since programmed efferocytosis in 
BMDM requires expression of Mer and Gas6, we predicted that de 
novo protein synthesis was required for programmed efferocytosis 
in HMDM. To test the requirement for protein synthesis, HMDM 
were treated with and without the protein synthesis inhibitor 
cycloheximide prior to being fed apoptotic targets. Cycloheximide 
inhibited C1q-dependent enhanced efferocytosis in HMDM 
demonstrating that protein synthesis is required for programmed 
efferocytosis in HMDM (Figures  3A,B, n =  4). C1q triggers a 
direct enhancement of phagocytosis of antibody-coated particles 
which occurs within 5  min of stimulation with C1q (18). As 
expected, cycloheximide treatment did not inhibit C1q-dependent 
enhanced engulfment of antibody-coated targets indicating that 
the cycloheximide did not inhibit all C1q-dependent pathways, or 
phagocytosis in general (Figure 3C, n = 3).
Mer and axl are Upregulated in Mouse 
Macrophages but not human 
Macrophages
Since Mer is required for programmed efferocytosis in BMDM, 
and Mer and other members of the TAM family of receptor 
tyrosine kinases also downregulate proinflammatory signaling, 
FigUre 4 | Mer and axl expression are upregulated after prolonged c1q stimulation in BMDM, but not hMDM. (a) BMDM were adhered to LTC slides 
coated with 4 μg/ml HSA (control) or C1q for 18 h and Mer and Axl were detected from lysates by western blot. Actin was measured as a loading control. Blot is 
representative of three separate experiments. (B) Densitometric analysis of experiments (ImageJ) described in (a), normalized to actin ± SEM. **p < 0.01; 
***p = 0.001 (c) HMDM were cultured in LTC slides coated with 8 μg/ml HSA (control) or C1q for 18 h and Mer and Axl expression were detected from lysates by 
western blot. Actin was measured as a loading control. Blot is representative of two separate experiments.
FigUre 3 | c1q-dependent efferocytosis requires protein synthesis. (a) HMDM were adhered to LTC slides coated with 8 μg/ml HSA (control) or C1q for 
30 min and 100 μM cycloheximide (CHX) was added for 4 h. CFSE-labeled apoptotic Jurkats were then added at a 3:1 ratio of targets to macrophages for 1 h and 
efferocytosis was quantified by flow cytometry. Bars represent the mean of four individual experiments ± SEM. ***p < 0.001; n.s. = not significant.  
(B) Representative flow cytometry scatter plots from an experiment as described in (a). (c) HMDM were cultured in LTC slides coated with 8 μg/ml HSA (control) or 
C1q for 30 min and fed EAIgG for 30 min. Cells were fixed and at least 200 cells/well from duplicate wells were scored by microscopy. Bars represent the mean of 
three individual experiments ± SEM. ***p < 0.001.
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we evaluated the expression of Mer in C1q-dependent regula-
tion of proinflammatory signaling. As shown previously in Ref. 
(5) and represented in Figures  4A,B, 18-h stimulation with 
C1q resulted in upregulated expression of Mer in BMDM. The 
related TAM family kinase, Axl, was also upregulated in C1q-
stimulated BMDM (Figures 4A,B, n = 3). However, the HMDM 
failed to upregulate Mer and Axl when stimulated with C1q for 
18  h (Figure  4C; Figure S2 in Supplementary Material). These 
studies suggest that unlike BMDM, programmed efferocytosis in 
HMDM is independent of Mer (or Axl) upregulation.
Programmed efferocytosis and inhibition  
of Proinflammatory signaling requires  
Full-length c1q
C1q stimulates a direct enhancement of phagocytosis of 
antibody-opsonized targets, and this pathway is activated by the 
C1q collagen-like tails. Arora et al. (22) identified a conserved six-
amino acid sequence in the collagen-like tail of C1q (and related 
defense collagens) that is required for the phagocytic function. 
In our previous studies, the collagen-like tail failed to program 
FigUre 5 | Programmed efferocytosis and inhibition of proinflammatory signaling requires full-length c1q. (a) HMDM were adhered to LTC slides 
coated with 8 μg/ml HSA (control), C1q, or C1q-Tails for 30 min and fed EAIgG. Phagocytosis was allowed to occur for 30 min and percent phagocytosis was 
measured from at least 200 cells/well from duplicate wells. Bars represent the mean of three separate experiments normalized to control ± SEM. **p < 0.01. (B) 
HMDM were cultured in LTC slides coated with 8 μg/ml HSA (control), C1q, or C1q-Tails for 18 h and fed CFSE-labeled apoptotic Jurkats at a 3:1 ratio of targets to 
macrophages for 1 h. Efferocytosis was quantified by flow cytometry. Bars represent the mean of three individual experiments normalized to control ± SEM. 
**p < 0.01; n.s. = not significant (c) Representative flow cytometry scatter plots from an experiment as described in (B). (D) HMDM were adhered to LTC slides 
coated with 8 μg/ml HSA (control), C1q, or C1q-Tails for 18 h and stimulated with 300 ng/ml LPS for 4 h. TNF-α was quantified from supernatants by ELISA. Bars 
represent the mean of three separate experiments normalized to control ± SEM. *p < 0.05; n.s. = not significant (e) BMDM were adhered to LTC slides coated with 
4 μg/ml HSA (control), C1q, or C1q-Tails for 18 h and stimulated with 300 ng/ml LPS for 4 h. TNF-α was quantified from supernatants by ELISA. Bars represent the 
mean of three separate experiments normalized to control ± SEM. *p < 0.05; n.s. = not significant.
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enhanced efferocytosis in BMDM (2). To determine if the 
collagen-like tails were sufficient for the regulation of proinflam-
matory signaling, we confirmed that the tails were functional in 
a phagocytosis assay using antibody-opsonized sheep red blood 
cells (EAIgG). C1q-tails and full-length C1q stimulated compara-
ble levels of phagocytosis of EAIgG in HMDM (Figure 5A). C1q-
tails stimulated 1.4- to 3-fold enhanced phagocytosis of EAIgG, 
and C1q stimulated 1.7- to 2.6-fold enhanced phagocytosis of 
EAIgG (n = 3). Similar to BMDM, programmed efferocytosis in 
HMDM required the full-length molecule since the collagen-like 
tails failed to stimulate enhanced efferocytosis (Figure 5B). C1q 
treatment resulted in a 3.8-fold enhancement of efferocytosis in 
HMDM, whereas there was not a significant difference in engulf-
ment between control cells and cells treated with the C1q-tails 
(n = 3). In addition, while full-length C1q programmed a down-
regulation of LPS-dependent TNFα production, the collagen-like 
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tails failed to downregulate proinflammatory signaling in both 
human (Figure 5D) and mouse (Figure 5E) macrophages. There 
was a 34–45% range of inhibition of TNFα production from 
human macrophages treated with C1q (n =  3) and a 28–33% 
range of inhibition of TNFα production from mouse mac-
rophages (n = 3). No significant difference in TNFα production 
was detected between human or mouse control macrophages and 
C1q-tails-treated macrophages. These data indicate that the C1q 
collagen-like tails are insufficient for mediating C1q-dependent 
programming of enhanced efferocytosis and inhibition of TNFα 
production.
DiscUssiOn
The objective of this study was to investigate the role of program-
ming on C1q-dependent enhancement of efferocytosis and inhibi-
tion of proinflammatory signaling in mouse and human primary 
macrophages. To accomplish this objective, we used mouse 
BMDM, or primary human monocyte-derived macrophages 
(HMDM), to investigate the contribution of prolonged stimula-
tion with C1q on macrophage efferocytosis and production of 
proinflammatory cytokines. Mouse and human macrophages 
were adhered to C1q for either 30 min or 18 h (prolonged stimula-
tion), followed by a 4  h stimulation with LPS, and production 
of TNFα and IL-6 was measured by ELISA. While mouse mac-
rophages required prolonged stimulation with C1q in order to 
downregulate TNFα production, human macrophages responded 
immediately to C1q (within 30  min) to dampen LPS-induced 
TNFα production. Interestingly, IL-6 production was significantly 
enhanced in HMDM, but only after 18 h programming with C1q 
(Figure 1). Fraser and colleagues previously reported enhanced 
IL-6 expression in human monocytes after 18 h stimulation with 
C1q in the presence of LPS (18). These data suggest that there 
are multiple mechanisms leading to C1q-dependent regulation 
of proinflammatory cytokine production involving both immedi-
ate responses and responses that require prolonged stimulation. 
Interestingly, the same is true for C1q-dependent phagocytosis 
where enhanced phagocytosis of antibody-opsonized particles 
occurs within minutes of stimulation with C1q (18), whereas 
C1q also regulates gene expression in macrophages leading to 
enhanced engulfment of apoptotic cells (5).
Our previous studies demonstrated that prolonged stimula-
tion with C1q resulted in the development of a pro-efferocytic 
phenotype in mouse BMDM (5). Similar to the mouse cells, 
human macrophages (but not human monocytes) responded to 
prolonged stimulation with C1q with enhanced efferocytic func-
tion (Figure 2). C1q-dependent enhanced efferocytosis required 
a change in protein expression since cycloheximide inhibited 
the pro-efferocytic phenotype. Our previous studies indicated 
that programmed efferocytosis in mouse BMDM resulted from 
C1q-dependent expression of Mer tyrosine kinase and Gas6; 
however, the human macrophages did not upregulate Mer or the 
related TAM family receptor, Axl, in response to C1q following 
18 h stimulation (Figure 4C). Therefore, the mechanism leading 
to C1q-dependent programmed efferocytosis in mouse is likely 
different from human; however, different cell culture conditions 
or time points may reveal a role for TAM receptors that was not 
detected here. In any case, our data suggest that C1q stimulates 
the expression of pro-efferocytic molecules in both systems. 
Consistent with this observation, Majai et al. (10) demonstrated 
that macrophages from lupus patients have decreased expression 
of pro-efferocytic molecules. Furthermore, while C1q-dependent 
engulfment of apoptotic cells required Mer tyrosine kinase, we 
observed that multiple engulfment molecules were upregulated 
by C1q in our initial array, including C1q itself and MFG-E8 (5). 
Therefore, C1q may stimulate expression of different engulfment 
molecules under different conditions or microenvironments 
leading to development of a pro-efferocytic phenotype. Since C1q 
deficiency results in a lupus-like disease [reviewed in Leffler et al. 
(23)], it is possible that the lack of C1q in lupus patients results 
in the maturation of macrophages that are defective in clearance 
of apoptotic cells because they fail to express or upregulate the 
critical engulfment proteins.
The TAM family of receptors regulate the clearance of 
apoptotic cells, and this family also regulates the inhibition of 
proinflammatory signaling (11), similar to C1q. Therefore, we 
assessed expression of Mer and the related family member, Axl, 
in BMDM and HMDM. Unlike mouse macrophages, the human 
macrophages failed to upregulate expression of Mer and Axl 
indicating that the alteration of cytokine signaling in these cells 
was independent of Mer/Axl expression. Similarly, expression of 
LPS receptors TLR4 and CD14 was not altered in C1q-stimulated 
mouse macrophages (data not shown) indicating that the defect 
in signaling was downstream of the LPS receptors. Fraser et al. 
(21) previously demonstrated that C1q stimulated the activity 
of inhibitory NFκB complexes leading to a dampening of pro-
inflammatory cytokine production in human monocytes, so it is 
possible that the defect in proinflammatory signaling in human 
and mouse macrophages occurs at the level of transcription. Our 
current studies are focusing on the molecular mechanisms of 
C1q-dependent signaling.
The initial step in the signal transduction pathway down-
stream of C1q is the binding of C1q to the cell; however, the C1q 
receptors responsible for mediating C1q-dependent efferocytosis 
or inflammatory signaling have yet to be identified. We previously 
demonstrated that C1q-dependent programming of efferocytosis 
in mouse BMDM was independent of several of the described 
C1q receptors (5, 15). Therefore, to begin to define the signal 
transduction pathway required for C1q-dependent program-
ming, we have taken two directions: (1) to identify intracellular 
signaling pathways downstream of C1q binding (15) and (2) to 
characterize the important domains on C1q that are required to 
mediate C1q-dependent signaling. Our previous studies demon-
strated that C1q-dependent upregulation of efferocytosis requires 
activation of AMP-activated protein kinase (AMPK) (15), and our 
preliminary studies suggest that AMPK is similarly activated in 
HMDM (data not shown). In addition, the collagen-like tails were 
not sufficient for upregulating expression of Mer or enhancing 
efferocytosis in BMDM (15). Here, we demonstrated that the full-
length molecule was also required for the dampening of TNFα 
production in both mouse and human macrophages and enhanced 
efferocytosis in human macrophages, since the collagen-like tails 
failed to inhibit C1q-dependent downregulation of proinflam-
matory cytokine production or increase efferocytosis in HMDM 
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(Figure 5). It has not been determined if the C1q globular heads 
are sufficient for upregulating efferocytosis or regulating cytokine 
production; however, we demonstrated that adiponectin, a C1q 
homolog, could also upregulate Mer-dependent efferocytosis 
(15) and the adiponectin heads were not sufficient for mediating 
this activity (data not shown). Therefore, these C1q-dependent 
functions may require a full-length molecule.
It has been known for nearly 30 years that C1q provides an 
immediate signal for enhancement of phagocytic function (24), 
and C1q has been studied extensively as a physical bridging 
molecule between macrophages and apoptotic cells [reviewed 
in Galvan et  al. (2)]. However, more recently, we have begun 
to appreciate the programming activity of C1q, which sug-
gests that C1q programs macrophages for a pro-resolving and 
 anti-inflammatory phenotype [reviewed in Bohlson et al. (1)]. It 
is becoming clear that C1q functions through multiple pathways, 
including the activation of the classical complement pathway, 
directly opsonizing for phagocytosis, and directly regulating 
gene expression. Moreover, C1q has different activities in mice 
and humans since C1q deficiency in humans results in lupus with 
nearly 100% penetrance, whereas the development of autoim-
munity in mice is highly dependent on genetic background (25). 
Elucidating the molecular pathways involved in C1q-dependent 
functions in mouse and human cells should help in identifying 
new methods for targeting autoimmune diseases and chronic 
inflammation.
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